ArticleBiomaterials translational2023
Harvest of functional mesenchymal stem cells derived from
Article in Biomaterials translational, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- BMP-2-driven osteo-organoid formation retains key osteogenic-support features and promotes bone repair following total-body irradiation.Bioactive materials · 2027Article
- Schisandrin B alleviates osteoporosis by regulating gut microbiota homeostasis.Molecular and cellular biochemistry · 2026Article
- Development-based In Vivo Bioreactor Strategy for Challenging Senescent Bone Reconstruction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Toward system-level integration of organoids for regenerative medicine.Burns & trauma · 2026Review
- H3K27 Acetylation-driven IGF2BP2 Mutates during the Aging of MSCs, thereby Influencing Osteogenic Differentiation and Bone Aging.International journal of biological sciences · 2026Article
- Sequentially assembled co-delivery nanoplatform of SIRT1 protein and SOX9-expressing plasmid for multipronged therapy of intervertebral disc degeneration.Journal of nanobiotechnology · 2025Article
- Extracellular Vesicles in Gut-Bone Axis: Novel Insights and Therapeutic Opportunities for Osteoporosis.Small science · 2025Review
- Organoid, organ-on-a-chip and traditional Chinese medicine.Chinese medicine · 2025Review
- Effects of Insulin-like Growth Factor 1 on the Maintenance of Cell Viability and Osteogenic Differentiation of Gingiva-Derived Mesenchymal Stem Cell Spheroids.Medicina (Kaunas, Lithuania) · 2025Article
- Specnuezhenide Alleviates Senile Osteoporosis by Activating TGR5/FXR Signaling in Bone Marrow Mesenchymal Stem Cells and RANKL-Induced Osteoclasts.Drug design, development and therapy · 2025Article
- 3-D bioprinted human-derived skin organoids accelerate full-thickness skin defects repair.Bioactive materials · 2024Article
- Amphiphilic cytokine traps remodel marrow adipose tissue for hematopoietic microenvironment amelioration.Bioactive materials · 2024Article
- In situ licensing of mesenchymal stem cell immunomodulatory function via BMP-2 induced developmental process.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Exosomes on the development and progression of renal fibrosis.Cell proliferation · 2024Review
- IRE1α pathway: A potential bone metabolism mediator.Cell proliferation · 2024Review
- Future perspectives: advances in bone/cartilage organoid technology and clinical potential.Biomaterials translational · 2024Review
- Extracellular Vesicles Derived from HDrug design, development and therapy · 2024Article
- Extracellular vesicles from apoptotic BMSCs ameliorate osteoporosis via transporting regenerative signals.Theranostics · 2024Article
- Large scale, high purity, high quality isolation of mesenchymal stem cells from osteo-organoids.Biomaterials translational · 2024Article
- Advance in the application of organoids in bone diseases.Frontiers in cell and developmental biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow-derived mesenchymal stem cells (BM-MSCs) play a crucial role in stem cell therapy and are extensively used in regenerative medicine research. However, current methods for harvesting BM-MSCs present challenges, including a low yield of primary cells, long time of in vitro expansion, and diminished differentiation capability after passaging. Meanwhile mesenchymal stem cells (MSCs) recovered from cell banks also face issues like toxic effects of cryopreservation media. In this study, we provide a detailed protocol for the isolation and evaluation of MSCs derived from in vivo osteo-organoids, presenting an alternative to autologous MSCs. We used recombinant human bone morphogenetic protein 2-loaded gelatin sponge scaffolds to construct in vivo osteo-organoids, which were stable sources of MSCs with large quantity, high purity, and strong stemness. Compared with protocols using bone marrow, our protocol can obtain large numbers of high-purity MSCs in a shorter time (6 days vs. 12 days for obtaining passage 1 MSCs) while maintaining higher stemness. Notably, we found that the in vivo osteo-organoid-derived MSCs exhibited stronger anti-replicative senescence capacity during passage and amplification, compared to BM-MSCs. The use of osteo-organoid-derived MSCs addresses the conflict between the limitations of autologous cells and the risks associated with allogeneic sources in stem cell transplantation. Consequently, our protocol emerges as a superior alternative for both stem cell research and tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.